Digital Signature in Motihari @ Best Prices

Please Contact Sonu: 8745810407

 What is Class 2 Individual User Signing ONLY Digital Signature Certificate ? 

Class 2 Individual User Digital Signature is crafted for Personal Use. Signing ONLY is One of the Type of Certificates available. Class 2 Individual User Signing DSC is mainly acceptable for Income Tax Return e-Filing, ROC e-Filing, DVAT e-Filing, Service Tax Return e-Filing, Provident Fund e-Filing, IEC Registration on DGFT Website. On some limited e-Tendering / e-Procurement websites, Class 2 Individual User Signing DSC can be work.

 Departments / Website who Currently Accepting Class 2A Signing DSC 

  • GST : For GST Registration , GST Return e-Filing
  • Income Tax Department : For e-Filing of Income Tax Return.
  • Ministry of Corporate Affairs : For e-Filing of Forms / For Company Incorporation
  • Employee’s Provident Fund Organization : To Transfer Provident Fund of Employees through EPFO Website.
  • TRACES : To Sign Form 16/16A for TDS Purposes.
  • SEZ Online : To Sign all applications & claims submitted & processed online through SEZ Online system.
  • DVAT : For e-Filing of VAT Returns
  • DGFT : For Fresh IEC Registration

 Technical Specifications of Class 2A SIGNING DSC 

  • Class of DSC : Class 2
  • Type of Certificate : Signing ONLY
  • Validity of DSC : Minimum 1 Years & 2 Years Maximum
  • User Types : Individual User
  • Bits of DSC : 2048 Bit
  • Algorithm of DSC : SHA 2
  • Storage of DSC : ON FIPS Certified Cryptographic USB Tokens

 Suggested Usages* : 

  • For GST , Income Tax Return e-Filing
  • For MCA / ROC e-Filing
  • For Fresh DGFT IEC Registration
  • For Provident Fund(PF) e-Filing

 

An ever evolving Electronic media

Digital Marketing In 2017: B2B Trends and Stats Of The Year

With the time, digital marketing is surpassing its barriers and giving businesses new, impressive promotional methods. This left experts and digital marketers eager about data on new trends to develop new strategies. It is easy to collect data on business to consumer and make new strategy than finding B2B trends. But understanding B2B trends are necessary to speed up their digital marketing efforts. Here’s important information on B2B digital marketing statistics for 2017:

Email marketing and content marketing are still leading the race of effective tactics, as per the survey. About 89% B2B researchers have admitted content marketing as a great strategy. More than 50% have also said that content marketing is more powerful today than it was last year.

More than 90% B2B researchers believe email marketing is the most-used distributed channel. They also suggest that over half of the total emails are read through smartphones.

More than 70% researchers in B2B consider generic Google search to start with.

More than 50% of these researchers have been found to be Millennials.

LinkedIn is an effective platform for B2B marketing. On the other side, only one-third brands of B2B use photo-sharing app Instagram, but it has higher interaction rate than other platforms.

Smartphone has been notified as an important tool by more than 80% of the Millennials. Although baby boomers have different option as only 60% of them say smartphone is important.

About half of the B2B companies have a responsive website. It suggests that companies that will soon have responsive website could taste success in a short interval of time.

About offline marketing, the 2017 trends show that only 58% B2B marketers believe in advertising and print methods. In addition, less than one fourth of the users think the offline marketing is an effective tool.

 

Celgene Corporation to Webcast

Celgene Corporation to Webcast at Upcoming Investor Conferences

SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ:CELG) plans to present at four upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company’s website at www.celgene.com.

Wednesday, September 6, 2017, Celgene will present at the Baird Global Healthcare Conference in New York City at 3:45 pm ET

Wednesday, September 13, 2017, Celgene will present at the Morgan Stanley Global Healthcare Unplugged Conference in New York City at 9:20 am ET

Thursday, September 14, 2017, Celgene will present at the Bank of America Merrill Lynch Global Healthcare Conference in London at 11:10 am ET

Tuesday, September 26, 2017, Celgene will present at the Cantor Fitzgerald 3rd Annual Healthcare Conference in New York City at 9:45 am ET

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit www.celgene.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Hyperlinks are provided as a convenience and for informational purposes only. Celgene bears no responsibility for the security or content of external websites.

Contacts

Celgene Corporation
Patrick E. Flanigan III, 908-673-9969
Corporate VP, Investor Relations
or
Celgene Corporation
Brian Gill, 908-673-9530
VP, Corporate Communications